^
    Back
    Association details:
    Biomarker:HRD + BRCA2 mutation
    Cancer:Ovarian Cancer
    Drug:Zejula (niraparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study.

    Published date:
    05/25/2023
    Excerpt:
    Results suggest that long-term PFS in pts treated with niraparib may be associated with BRCA/HRd biomarker status, FIGO stage, primary tumor site, and number of baseline non-target lesions.
    DOI:
    10.1200/JCO.2023.41.16_suppl.5589
    Trial ID:
    PRIMA
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Lancet
    Title:

    Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Excerpt:
    We observed clinically relevant activity of niraparib among women with heavily pretreated ovarian cancer, especially in patients with HRD-positive platinum-sensitive disease, which includes not only patients with a BRCA mutation but also a population with BRCA wild-type disease.
    DOI:
    10.1016/S1470-2045(19)30029-4